Learn More About Silence’s Broad RNAi Therapeutic Platform
 
 

Review One of the Industry’s Broadest RNAi Clinical Pipelines
 
 
     
      Webcast - Corporate Update
Rodman & Renshaw 6th Annual Global Healthcare Conference - May 18, 2010

19.08.10
Silence Therapeutics’ Partner Quark Signs Exclusive Option Agreement with Novartis for Development and Commercialisation of QPI-1002

11.08.10
Silence Therapeutics Adds New Patent to Industry Leading Structural Modification Intellectual Property Portfolio